In this study, we developed a noninvasive CT-based radiomics model to predict the outcomes of anti-PD-1 therapy in patients with advanced gastric cancer, distinguish the responders from non-responders to PD-1 inhibitor treatment and predict patient survivals before therapy. This evidence concerns the gene PDCD1 and gastric cancer.